Number of pages:
Parameters | Details |
---|---|
Base Year |
2021 |
Historical Data |
2016-2021 |
Forecast Data |
2022-2028 |
Base Year Value (2021) |
USD million |
Forecast Value (2028) |
USD million |
CAGR (2022 to 2028) |
% |
Regional Scope |
North America, Europe, Asian Pacific, Latin America, Middle East and Africa, and ROW |
Global Urological Cancer Therapeutics Drugs Market is estimated to reach USD 53.65 billion by 2026, growing at a CAGR of 10.5 % between 2018 and 2026
Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs. In male prostate cancer is more common of these malignancies. Basically in urological cancer there is the growth of abnormal tissues in bladder, prostate, penile, testicular or kidney. This abnormal growth of tissues is referred to as tumours, which even spreads into the surrounding tissues or muscles.
The urological cancer market is segmented into cancer type, treatment type, end-user, and geography.There are different types of urological cancers such as kidney, prostate, testicular and bladder cancer. On the basis of type of treatment, the market is divided into chemotherapy, hormonal therapy, and surgery & radiation therapy. Depending on end-user, the market is divided into hospitals, urological cancer medical research laboratory and others. Top players of this market are Novartis, Pfizer, Johnson & Johnson, Astra Zeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline plc, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare and Sanofi S.A.
Geographically, Global Urological Cancer Therapeutics Drugs market is classified as North America, Europe, Southeast Asia , China, Japan and India. Currently, North America dominates the urological cancer market because of increasing geriatric population, available advanced health care solutions, new product innovations, well developed healthcare infrastructure and technological advancements. North America is followed by Europe due to research and development activities and at the same time increasing consumption of alcohol and smoking behaviour.
Urological Cancer Therapeutics Drugs Market : Product Type
Urological Cancer Therapeutics Drugs Market : Application
Global Urological Cancer Therapeutics Drugs Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Global Urological Cancer Therapeutics Drugs Market:
Geographical analysis of Urological Cancer Therapeutics Drugs Market:
Urological Cancer Therapeutics Drugs Market Report delivers comprehensive analysis of :
Urological Cancer Therapeutics Drugs Market was valued at around USD million in 2021 & estimated to reach USD by 2028.
Urological Cancer Therapeutics Drugs Market is likely to grow at compounded annual growth rate (CAGR) of % between 2022 to 2028.
Yes, the report includes COVID 19 impact on the market.
Precise research methodology, numerous analysis models & up to date data resources to achive most accurate market values.
We can tailored the report as per your requirments & budget, Most of our clients prefer custom reports.
We have quality market data for all types of budget & so now get best out of your market research budget.
Be assured of receving satisfactory analyst support to understand research report in-detail.